China-based CanSino Biologics Inc., (HKG: 6185) announced that the National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for its CRM197, a 13-valent pneumococcal polysaccharide conjugate vaccine (TT vector).
Vaccine Technology
PCV13i utilizes covalent conjugation technology to link polysaccharide antigens to protein carriers, transforming them into T-cell-dependent antigens. This process induces high levels of specific antibodies and establishes immune memory.
Proprietary Advantages
The vaccine employs CanSino’s proprietary dual-carrier conjugation technology, which enhances immunogenicity. Additionally, the production process incorporates animal component-free fermentation and expression systems. This approach reduces risks linked to animal-derived biological factors and avoids potential toxic residues from traditional purification methods.-Fineline Info & Tech
